Stock data
Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals, Inc. (RIGL) reported revenue of US$294.28M and net income of US$367.02M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$294.28M | — | US$125.47M | US$367.02M | — |
| 2024 | US$179.28M | — | US$24.19M | US$17.48M | — |
| 2023 | US$116.88M | — | -US$20.49M | -US$25.09M | — |
| 2022 | US$120.24M | — | -US$55.55M | -US$58.57M | — |
| 2021 | US$149.24M | — | -US$12.50M | -US$17.91M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$78.70M | US$17.29M | — |
| 2026-03-31 | US$58.82M | US$8.65M | — |
| 2025-12-31 | US$69.80M | US$268.06M | — |
| 2025-09-30 | US$69.46M | US$27.90M | — |
| 2025-06-30 | US$101.69M | US$59.61M | — |
| 2025-03-31 | US$53.33M | US$11.45M | — |
| 2024-12-31 | US$57.60M | US$14.34M | — |
| 2024-09-30 | US$55.31M | US$12.42M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.